title: Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system.
abstract: BACKGROUND
  Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl™) was previously shown to competitively inhibit mushroom and human tyrosinase in vitro without the associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma.
  
  
  OBJECTIVE
  The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oligopeptide cream, an antioxidant cleanser, 20% glycolic acid lotion and physical sunscreen) accelerates clearance of mild-to-moderate melasma.
  
  
  RESULTS
  All patients showed improvement in their facial melasma with 1 of 4 patients showing complete clearance after just 6 weeks.
  
  
  CONCLUSIONS
  Results suggest that this regimen may be a useful new tool to treat mild to moderate melasma.
authors.affiliation: Elixir Institute of Regenerative Medicine, San Jose, CA, USA. basil@elixirinstitute.org
authors.forename: Basil M
authors.initials: BM
authors.lastname: Hantash
authors.forename: Felipe
authors.initials: F
authors.lastname: Jimenez
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005145:Face; D005260:Female; D006801:Humans; D008297:Male; D008548:Melanosis / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; C543573:Lumixyl; D009842:Oligopeptides